


## Supplementary Materials: Development of Scaffolds with Adjusted Stiffness for Mimicking Disease-Related Alterations of Liver Rigidity

Marc Ruoff <sup>1,\*</sup>, Silas Rebholz <sup>1</sup>, Marina Weimer <sup>1,2</sup>, Carl Grom-Baumgarten <sup>1</sup>, Kiriaki Athanasopulu <sup>2</sup>, Ralf Kemkemer <sup>2</sup>, Hanno Käß <sup>3</sup>, Sabrina Ehnert <sup>1</sup> and Andreas K. Nussler <sup>1</sup>

**Table S1.** Concentrations of cryogel components which were tested during the development of the scaffolds.

Scaffold Component	Final Concentration Within the Cryogel
ddH <sub>2</sub> O	adapted to the other scaffold components
2-HEMA 98%	1%–30%
BAA 2%	ratio 1:1 – 1:6 adapted to the HEMA concentration
Gelatin (300 g/L)	0%–40%
BSA (100 g/L)	0%–60%
Collagen (3.5 g/L)	0%–40%
TEMED	2%
APS 10%	0.2%
Glutaraldehyde 25%	0%–2.5%

### Measurement of the Scaffold Permeability



**Figure S1.** The diffusion rate of the red-colored SRB solution into the scaffold was used to determinate the permeability of the scaffolds. The figure shows representative images of the cross-section of the healthy liver scaffold. These images were used for the analysis of the scaffold permeability.